“The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” said the NIAID statement released early Tuesday.
“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”
In a statement Tuesday, AstraZeneca said the numbers shared Monday were based on a pre-specified interim analysis with a data cutoff of February 17. It said it has reviewed an early assessment of its primary analysis, and those results were consistent with the interim analysis.
“We will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up to date efficacy data,” the statement said. “We intend to issue results of the primary analysis within 48 hours.”
Last year, the National Institutes of Health appointed a common DSMB to monitor Covid-19 vaccine clinical trials that were being funded by the federal government — including AstraZeneca, Moderna and Johnson & Johnson. This DSMB has 10 to 15 members with specialties including vaccine development, statistics and ethics.
Fauci said on Good Morning America on Tuesday that when the DSMB saw AstraZeneca’s press release, “they got concerned and wrote a rather harsh note to them — and with a copy to me — saying that in fact they felt that the data that was in the press release were somewhat outdated and might in fact be misleading a bit, and wanted them to straighten it out.”
‘Unforced error’ could create doubt about vaccine
The press release from AstraZeneca was “an unforced error” that may create doubt about what “is very likely a very good vaccine,” Fauci said. The data are “really quite good, but when they put it into the press release, it wasn’t completely accurate.”
The fact that the DSMB picked up on the discrepancy was an example of a safeguard around vaccines, Fauci said.
But having seen the monitoring board’s letter, “we could not just let it go unanswered.”
Still, a public statement questioning AstraZeneca’s data is unusual.
DSMBs sometimes disagree with investigators over the interpretation of trial results, Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said in a statement to the Science Media Centre in the UK. But that’s usually done in private, he said, “so this is unprecedented in my opinion.”
Dr. Peter Hotez, a vaccine expert and dean of tropical medicine at Baylor school of medicine, told CNN the NIAID statement was “totally strange.”
“I can barely understand the dispute or why they would make it so public,” Hotez said. “My concern is that this will further erode public confidence in the AZOX vaccine, especially for low and middle income countries. And we don’t have many options for Africa and Latin America at this point.”
This is not the first time AstraZeneca has faced questions about its Covid-19 vaccine. In November, it was revealed that a mistake was made in the trial and some participants received the wrong dose.
More recently, a number of European countries including Norway, France and Denmark temporarily suspended their AstraZeneca vaccine rollouts due to reports of blood clotting in patients.
An emergency investigation by the European Medicines Agency concluded the benefits of the vaccine outweigh the risks, saying the vaccine is “safe and effective” in preventing coronavirus and “not associated with an increase in the overall risk of thromboembolic events, or blood clots.”
There’s no indication the DSMB concerns noted in the NIAID statement were linked to safety issues with the AstraZeneca vaccine.
EUA application expected in April
On Tuesday, White House senior adviser for Covid response Andy Slavitt attempted assure the public that any vaccine that’s authorized will be safe and effective.
“We’re talking about now a fourth vaccine that’s not yet approved by the FDA. And the reason we have an FDA process is exactly so that we don’t have to wonder about data. We don’t have to take a company’s word for it, with all respect to the companies,” Slavitt said during an interview on CNN Tuesday.
“The public should rest assured that nothing will get approved unless the FDA does a thorough analysis of this data, and when it does that thorough analysis, it will render a judgment on both what the data says, or what it’s saying, and also whether or not it will be approved.”
Naomi Thomas, Nadia Kounang, Jo Shelley and Jason Hoffman contributed to this report.